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Background. Imatinib mesylate is the gold standard for the treatment of all phases of Philadelphia-positive chronic myeloid
leukemia. Patients on imatinib treatment may develop cytopenia due to drug toxicity. *is study aimed to determine the types,
grades, and time course of cytopenia in CML patients on imatinib at a Nairobi hospital. Methods. *is was a cross-sectional
descriptive study of adult patients aged ≥18 years followed up at the Glivec International Patient Access Program (GIPAP) clinic
from 2007 to 2015. Patients who developed cytopenia within 12 months of initiating imatinib were eligible. Clinical and he-
matologic data were retrieved from the patients’ charts and entered into a study proforma. Measures of central tendency such as
mean, median, mode, standard deviation, and variance were used for analysis. Results. Sixty three percent (63.6%) of the 94
patients developed a monocytopenia, with anemia seen in 34%, neutropenia in 27.6%, and thrombocytopenia in 8% of the 94
patients. Anemia plus neutropenia was themost common bicytopenia at 12.7%. Pancytopenia was seen in only 5 of the 94 patients.
Most of the cytopenia was grades 2 and 3. Anemia was present at baseline while neutropenia and thrombocytopenia developed
within 12 months of imatinib initiation. Anemia resolved during the first 12 months of therapy while neutropenia and
thrombocytopenia resolved within 24–36 months of treatment. Conclusion. Monocytopenia, especially anemia, was the most
common type of cytopenia.*e cytopenia was predominantly grade 2, developed in majority of the patients within 6 months after
imatinib initiation, and had resolved by 24–36 months after imatinib initiation.
1. Introduction
Chronic myeloid leukemia (CML) is due to a clonal disorder
that causes granulocyte cell line proliferation [1]. It develops
following a translocation that occurs reciprocally between
two somatic chromosomes, t (9:22) [2]. *e fusion protein
resulting from this translocation, the BCR-ABL1, is a ty-
rosine kinase which acts independently of any stimulation
[3]. Tyrosine kinase inhibitors (TKI) used in the treatment of
CML block this kinase which in turn block signaling
pathways involved in proliferation while stimulating apo-
ptosis and cellular adhesion [4, 5]. Patients on imatinib, a
TKI, have been reported to develop cytopenia during the
course of treatment. Sneed, in their study of 143 CML
patients on imatinib, reported that neutropenia and
thrombocytopenia ≥grade 3 developed in 64 (45%) and 31
(22%) patients, respectively [6]. A study conducted in
Hyderabad among 683 CML patients aged between 21 and
75 years treated with imatinib reported that 46, 25, and 37
patients developed grade 2 anemia, neutropenia, and
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thrombocytopenia, respectively. Among them, 18 and 13
were reported as bicytopenia and pancytopenia, respectively
[7]. *e cytopenia was mild with majority of the patients
having grade 1 or 2 toxicity [7].
Most of the hematologic toxicities develop but also re-
solve early following the initiation of imatinib [8] and are
potentially reversible with either dose reduction or tem-
porary imatinib discontinuation. Severe hematologic tox-
icity may occur with higher doses of imatinib used in the
setting of imatinib resistance [9]. In the IRIS trial, the de-
velopment of new onset anemia, thrombocytopenia, and
neutropenia after 5 years of follow-up was rare at 4%, 9%,
and 17%, respectively, and diminished over time during
follow-up. In addition, grade 3 or 4 myelosuppression was
infrequent after the initial two years of therapy [10].
In the GIPAP clinic in Nairobi, several patients have
been reported to develop cytopenia immediately after
imatinib initiation. *ese patients are managed with either a
dose reduction or a treatment interruption.*is study aimed
to describe the type, grade, and time course of cytopenia
among patients treated with imatinib. It will add to the
scientific knowledge on types and grades of cytopenia and
aid in decision making for these patients.
2. Methods
2.1. Study Setting. *e Max access program provides free
imatinib to patients in Kenya at the GIPAP clinics. Cu-
mulatively, the clinic at the Nairobi hospital, Kenya, has
enrolled 1200 CML patients. An average of 150 patients
attend the clinic bi-weekly. *e clinic is centralized and
receives patients from the entire country. *e age range of
patients seen in the clinic is 6 to 75 years. *e males that
attend the clinic are in similar proportion to the females, and
almost 90% are in the chronic phase of CML. Patients who
initiate treatment are compliant with treatment with ad-
herence rates of approximately 80% [11].
2.2. Study Design and Population. *is was a cross-sectional
descriptive study of 94 patients. CML patients aged ≥18
years attending GIPAP clinic from 2007 to 2015 and on
imatinib 400mg daily who developed cytopenia ≥grade 2
were enrolled.
2.3.DataCollection. Data collection was conducted over a 3-
month period. Access to the files was limited to the principal
investigator (PI) and a trained study assistant. A coded
questionnaire was used as the study instrument to abstract
the information from the files. *e principal investigator
reviewed the data to ensure completeness and accuracy. *e
patient’s names were left out, and instead, each patient was
assigned a numerical identifier. Data were extracted from
2007 to 2015.
2.4. Data Management and Statistical Analysis. Data were
transferred into Microsoft Excel and imported into the
statistical analysis software for data management and
analysis. Continuous data were presented using means and
respective standard deviations (SD). Counts and corre-
sponding percentages were used for categorical variables.
Stata package, version 15.1, was used during statistical
analysis. Statistical tests were evaluated for significance at the
5% level (p< 0.05). Tables, bar charts, pie charts, and line
graphs were used to display results.
2.5. Variables. Cytopenia was determined from the com-
plete blood count (CBC) report of hemoglobin, neutrophil,
and platelet counts. Monocytopenia was defined as an ab-
normality in one parameter, bicytopenia as an abnormality
in two parameters, and pancytopenia as an abnormality in
three parameters based. Categorization of severity was based
on the National Cancer Institute Common Terminology
Criteria for Adverse Events v.3 (NCI CTAE v3) [12].
Time to development of cytopenia after initiation of
imatinib was categorized as less than 3 months, 3–6 months,
and 6–12 months while duration of cytopenia was deter-
mined from annual CBC reports over a 36-month period.
2.6. Ethical Considerations. Ethical approval was obtained
from the KNH/UON Ethics and Research Committee. Data
were stored in a password-protected computer. *e study
was a minimal risk study since there was no direct patient
involvement. For confidentiality, the patients’ charts were
used only within the confines of the records department of
the clinic.
3. Results
3.1. Type of Cytopenia. Sixty-six patients (63.6 %) among the
94 studied had a monocytopenia. Anemia developed in 32
(34%), neutropenia in 26 (27.6%), and thrombocytopenia in
8 (8%) of the 94 patients. Among patients with bicytopenia,
the most common type was anemia plus neutropenia in 12
(12.7%) patients, followed by neutropenia plus thrombo-
cytopenia in 8 (8%) patients and anemia and thrombocy-
topenia in 3 (3%) patients. Pancytopenia developed in 5
patients among the 94 studied.
3.2. Grade of Cytopenia. Grade 2 and 3 cytopenia were
equally common at 48.5% and 43.9%, respectively, as shown
in Table 1.
3.3. Time to Development of Cytopenia. *irty-seven (40%)
patients developed cytopenia within 3 months of initiating
imatinib, 33 (34.7%) within 3–6 months, and 24 (25.3%)
within 6–12 months.
3.4. Duration of Cytopenia. All grades of anemia improved
from the reported baseline and resolved within 12 months
(Figure 1). *rombocytopenia improved from 12 months
and had resolved by 36 months except in one patient
(Figure 2). Neutropenia also began to improve after 12
months for the affected patients and had resolved by 24–36
months (Figure 3).
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4. Discussion
*e study was conducted among 94 patients with cytopenia.
More patients developed monocytopenia (71%) than either
bicytopenia (24%) or pancytopenia (5%). Anemia was the
most common monocytopenia, and anemia plus neu-
tropenia was the most common bicytopenia. Pancytopenia
was seen in only 5 of the 94 patients. Grade 2 and 3 cytopenia
was common at 48.5% and 43.9%, respectively. Majority of
the cytopenia (74%) developed within six months of initi-
ating imatinib and resolved within 12months for anemia
and within 24–36 months for thrombocytopenia and neu-
tropenia. Our data are similar to that from India where
anemia developed in 46 (35%), thrombocytopenia in 34
(25%), neutropenia in 24 patients (17%), and bicytopenia in
18 patients. *is study included grade 2 to 4 cytopenia in the
analysis and was conducted in a low-resource setting similar
to ours [7]. Similarly, a different study from India reported
that anemia was the most frequent myelotoxicity and oc-
curred in 129 (65%) participants, followed by neutropenia in
57 (28%) and thrombocytopenia in 34 (17%) participants
[13]. In another trial, during the first 12months of treatment,
grade 3 and 4 toxicity was noted among the 532 study
participants. Neutropenia developed in 33%, thrombocy-
topenia in 18%, and anemia in 6% of the patients [8]. In
contrast, a study conducted in Indonesia reported lower
levels of cytopenia with anemia at 20%, thrombocytopenia at
14%, and neutropenia at 4% [14] while a study from Iraqi
documented anemia at 14%, and neutropenia and throm-
bocytopenia at 10% and 4% [15]. Lower proportions of
cytopenia reported in some studies may be due to the
analysis of patients with grade 3 and 4 cytopenia only. Earlier
diagnosis of CML in the developed world may also result in
lower levels of hematological toxicity.
Our study reported grade 2 and 3 cytopenia as the most
common grade. Similarly, an Indian study reported high
proportions of grade 2 cytopenia at 18.5%, 8.8%, and 10.3%
for anemia, neutropenia, and thrombocytopenia, respec-
tively, followed by grade 3 at 11.8%, 6.6%, and 7.4% for
anemia, neutropenia, and thrombocytopenia, respectively
[7]. Druker et al. reported lower levels of severe cytopenia
following imatinib therapy with grade 3-4 neutropenia at
14–19%, thrombocytopenia at 8–10%, and anemia at 3-4%
[10]. *e IRIS trial likewise reported severe cytopenia of
grade 3 or 4 to be low with anemia at 3%, neutropenia at
14.3%, and thrombocytopenia at 8% [16]. In contrast, a study
from Spain reported grade 3-4 cytopenia as being the
predominant grade [17], and Zhou et al. reported grade 3 to
4 neutropenia, anemia, and thrombocytopenia in 21.8%,
17.8%, and 5.9% of patients with CML, respectively [18].*e
presence of grade 3-4 toxicity may be due to presentation
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Figure 1: Median hemoglobin trends over a 36-month time period.
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Figure 2: Median platelet values over a 36-month time period.
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Figure 3: Median neutrophil values over a 36-month time period.
Table 1: Grades of cytopenia among the 66 patients with mon-
ocytopenia, NCI CTCAE, v3.
Variables Grade 2 Grade 3 Grade 4
Anemia (g/dL), n (%) 8–10 6.5–8 <6.517 (53) 13 (40.6) 2 (6.4)
Neutropenia (mm3), n
(%)
≥1000–1500 500–1000 <500
10 (38.5) 14 (53.8) 2 (7.7)
*rombocytopenia
(mm3), n (%)
50000–75000 25000–50000 <25000
5 (62.5) 2 (25) 1 (12.5)
Total, n (%) 32 (48.5) 29 (43.9) 5 (7.6)
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with advanced CML. Kantarjian et al. reported higher grades
of cytopenia in patients presenting with advanced chronic
phase-CML, with 35%, 20%, and 7% developing neu-
tropenia, thrombocytopenia, and anemia, respectively, of
grades 3 to 4 [19] while a similar study also reported that
advanced CML and high imatinib doses of 600mg were
associated with higher proportion of cytopenia [20].
Cytopenia developed within 3months of imatinib ini-
tiation in 40%, 3–6 months in 34.7%, and 6–12 months in
25% of the patients. Myelosuppression may develop at any
time during treatment of CML but is common in the initial
2–4 weeks of therapy, especially for advanced disease [21].
Other studies have reported onset of cytopenia between 3
and 5 weeks of imatinib therapy [22].
*e development of severe cytopenia rapidly in patients
with a myeloid bulge shortly after TKI initiation is a
phenomenon that is still under study. *e elevation of
leucocytes in these patients probably reflects the high
disease burden at diagnosis [19]. Once normal blood cell
formation resumes, the myelosuppression that has been
induced by TKI treatment resolves and the risk of devel-
oping myelosuppression later in the course of treatment
reduces. In addition, the blood and marrow laboratory
results often normalize in the course of follow-up [8]. *is
was reported in our study where there was recovery of
anemia, thrombocytopenia, and neutropenia at the end of
the 36-month follow-up. In other studies, grade 3 and grade
4 cytopenia resolved soon after treatment interruption and
did not recur with resumption of treatment [23]. *e IRIS
trial similarly reported that myelosuppression developed
early in the treatment course with imatinib therapy but had
resolved in the majority of patients after the first 12 months
of follow-up [24]. *e recovery of the cell counts within 12
months of initiating treatment could reflect bone marrow
normalization and regeneration [25]. However, some
isolated cases of recurrent myelosuppression requiring
extended treatment interruptions have been reported and
may be a consequence of advanced disease [17]. Con-
versely, the cytopenia may recover within days after its
development as has been documented prior where the
median duration of thrombocytopenia and neutropenia
was less than 3 weeks [23]. *e duration of cytopenia may
also be influenced by duration of CML prior to diagnosis. A
study reported that patients with long duration of CML
disease prior to diagnosis tended to have more advanced
disease. In the event of myelotoxicity in these patients, the
duration of cytopenia was more prolonged, especially with
higher grades of cytopenia [26].
In conclusion, monocytopenia was common, was of
grades 2 and 3, developed early in the course of treatment,
and resolved relatively early during follow-up. Clinicians
involved in the management of these patients should be alert
to diagnose, manage, and monitor these patients.
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